Viemed Healthcare Announces Key Data Affecting Patients With Chronic Obstructive Pulmonary Disease Presented by Dr. William F...
October 22 2019 - 05:00PM
Viemed Healthcare, Inc. (the “
Company” or
“
Viemed”) (TSX:VMD.TO and NASDAQ:VMD), a home
medical equipment supplier that provides post-acute respiratory
care services in the United States, announced that Dr. William
Frazier, pulmonologist and Chief Medical Officer for VieMed
Healthcare, presented results from the new study, The Impact of
Non-Invasive Ventilation (NIV) on Health Cost and Outcomes, at the
CHEST Annual Meeting 2019 in New Orleans. Dr. Frazier collaborated
with Precision Health Economics on this insightful study exploring
the effects of non-invasive ventilation at home (NIVH) for patients
with chronic obstructive pulmonary disease (COPD) and chronic
respiratory failure (CRF).
COPD is a common disease affecting over 16
million adults in the United States. As COPD progresses, many
patients develop CRF, which increases the risks of death and
hospitalization, reduces quality of life and increases healthcare
costs. While only a few treatment options are available to treat
this serious condition, NIVH has shown promise. The use of NIVH is
increasing, but fewer than five percent of patients with COPD and
CRF are currently receiving this treatment.
The study’s main objectives were to understand
the association of NIVH use with the risks of mortality,
hospitalizations and ER visits. According to Dr. Frazier, “This
study demonstrates that NIVH use in COPD-CRF patients is associated
with clinically important and statistically significant reductions
in mortality, hospitalization and ER visit rates.”
According to the results of the study, patients
receiving NIVH treatment had a 35 percent reduction in mortality as
opposed to 47 percent in the untreated population. NIVH treatment
also led to a drastic reduction in ER visits and
hospitalization.
The clinical implications derived from this
study show NIVH should be prescribed by physicians for those
patients with COPD-CRF, in order to increase their quality of life
and reduce mortality, unnecessary ER visits and costly
hospitalizations. The study is currently in peer review for
publication.
ABOUT VIEMED HEALTHCARE,
INC.
Viemed, through its indirect wholly-owned
subsidiaries Sleep Management, L.L.C. and Home Sleep Delivered,
L.L.C., is a home medical equipment supplier that provides
post-acute respiratory care services in the United States. Sleep
Management, L.L.C. focuses on disease management and improving the
quality of life for respiratory patients through clinical
excellence, education, and technology. Its service offerings are
based on effective home treatment with respiratory care
practitioners providing therapy and counseling to patients in their
homes using cutting edge technology. Home Sleep Delivered, L.L.C.
focuses on providing in-home sleep testing for sleep apnea
sufferers. Visit our website at www.viemed.com.
For further information, please contact:
Glen AkselrodBristol Capital905-326-1888
glen@bristolir.com
Todd ZehnderChief Operating OfficerViemed
Healthcare, Inc.337-504-3802
investorinfo@viemed.com
Forward-Looking Statements
Certain statements contained in this press
release may constitute “forward-looking statements” within the
meaning of the U.S. Private Securities Litigation Reform Act of
1995 or “forward-looking information” as such term is defined in
applicable Canadian securities legislation (collectively,
“forward-looking statements”). Often, but not always,
forward-looking statements can be identified by the use of words
such as “plans”, “expects”, “is expected”, “budget”, “potential”,
“scheduled”, “estimates”, “forecasts”, “intends”, “anticipates”, or
“believes”, “projects”, or the negatives thereof or variations of
such words and phrases or statements that certain actions, events
or results “will”, “should”, “may”, “could”, “would”, “might” or
“will be taken”, “occur” or “be achieved” or the negative of these
terms or comparable terminology. All statements other than
statements of historical fact, including those that express, or
involve discussions as to, expectations, beliefs, plans,
objectives, assumptions or future events or performance, are not
historical facts and may be forward-looking statements and may
involve estimates, assumptions and uncertainties that could cause
actual results or outcomes to differ materially from those
expressed in the forward-looking statements. Such statements
reflect the Company's current views and intentions with respect to
future events, and current information available to the Company,
and are subject to certain risks, uncertainties and assumptions.
Many factors could cause the actual results, performance or
achievements that may be expressed or implied by such
forward-looking statements to vary from those described herein
should one or more of these risks or uncertainties materialize.
These factors include, without limitation: the general business,
market and economic conditions in the regions in which the Company
operates; the Company may be subject to significant capital
requirements and operating risks; the ability of the Company to
implement business strategies and pursue business opportunities;
volatility in the market price of shares in the capital of the
Company; the Company’s novel business model; the risk that the
clinical application of procedures that demonstrate positive
results in a study may not be positively replicated or that such
test results may not be predictive of actual treatment
results; the state of the capital markets; the availability
of funds and resources to pursue operations; decline of
reimbursement rates; dependence on few payors; possible new drug
discoveries; dependence on key suppliers; granting of permits and
licenses in a highly regulated business; competition; low profit
market segments; disruptions in or attacks (including
cyber-attacks) on the Company's information technology, internet,
network access or other voice or data communications systems or
services; the evolution of various types of fraud or other criminal
behavior to which the Company is exposed; the failure of third
parties to comply with their obligations; difficulty integrating
newly acquired businesses; the impact of new and changes to, or
application of, current laws and regulations; the overall difficult
litigation environment; increased competition; changes in foreign
currency rates; increased funding costs and market volatility due
to market illiquidity and competition for funding; critical
accounting estimates and changes to accounting standards, policies,
and methods used by the Company; the Company’s status as an
emerging growth company and a foreign private issuer; and the
occurrence of natural and unnatural catastrophic events and claims
resulting from such events; as well as those risk factors discussed
or referred to in Viemed’s disclosure documents filed with the U.S.
Securities and Exchange Commission (the “SEC”) available on the
SEC’s website at www.sec.gov, including the Company’s Form 10 filed
with the SEC on August 1, 2019, and with the securities regulatory
authorities in certain provinces of Canada available at
www.sedar.com. Should any factor affect the Company in an
unexpected manner, or should assumptions underlying the
forward-looking statements prove incorrect, the actual results or
events may differ materially from the results or events predicted.
Any such forward-looking statements are expressly qualified in
their entirety by this cautionary statement. Moreover, the Company
does not assume responsibility for the accuracy or completeness of
such forward-looking statements. The forward-looking statements
included in this press release are made as of the date of this
press release and the Company undertakes no obligation to publicly
update or revise any forward-looking statements, other than as
required by applicable law.
Viemed Healthcare (TSX:VMD)
Historical Stock Chart
From Feb 2024 to Mar 2024
Viemed Healthcare (TSX:VMD)
Historical Stock Chart
From Mar 2023 to Mar 2024